Author:
Rajoli Rajith K. R.,Back David J.,Rannard Steve,Freel Meyers Caren L.,Flexner Charles,Owen Andrew,Siccardi Marco
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference53 articles.
1. UNAIDS. AIDS by the numbers 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pdf . Accessed 20 Oct 2014.
2. Palleja S, Ogden R, Hamy F, Vidal V, Klimkait T, Martin D, et al. In vitro anti-HIV efficacy of the chemokine receptor 5 (CCR5) antagonist TBR-652 in combination with four other classes of antiretroviral agents [poster no. 416]. 49th ICAAC; 12–15 Sep 2009; San Francisco.
3. Okwundu CI, Uthman OA, Okoromah CAN. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;(7):CD007189. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007189.pub3/abstract . Accessed 4 Dec 2014.
4. Spreen WR, Margolis DA, Pottage JCJ. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–71. doi: 10.1097/COH.0000000000000002 .
5. Boffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs. 2014;74(1):7–13. doi: 10.1007/s40265-013-0163-7 .
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献